Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-05-06
2000-01-11
Degen, Nancy
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 536 243, 536 2431, C07H 2104
Patent
active
06013786&
ABSTRACT:
The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent.
REFERENCES:
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5411860 (1995-05-01), Vogelstein
patent: 5550023 (1996-08-01), Kinzler et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5652356 (1997-07-01), Agrawal
Chen et al. Proc. Natl. Acad. Sci. U.S.A. 95:195-200 (1998).
Pon. Methods in Molec. Biol. 20:465 (1993).
Wu et al. Genes Dev. 7:1126-1132 (1993).
Sager et al. Science. 246:1406-1412 (1989).
Chen et al. Mol. Cell. Biol. 16:2445-2452 (1996).
Chen et al. Mol. Cell. Biol. 13:(7)4107-4114 (1993).
Marshall et al. Cell. 64:313-326 (1991).
Levine et al. Nature. 351:453-456 (1991).
Lane, Br. Med. Bull. 50:(3)582-599 (1994).
Lowe et al. Cell. 74:957-967 (1993).
Lowe et al. Science. 266:807-810 (1994).
Kastan et al. Cancer Res. 51:6304-6311 (1991).
Fritsche et al. Oncogene. 8:307-318 (1993).
Cahill-Snyder et al. Somatic Cell. Mol. Genet. 13:235-244 (1987).
Fakharadeh et al. EMBO J. 10:1565-1569 (1991).
Cordon-Cardo et al. Cancer Res. 54:794-799 (1994).
Ladanyi et al. Cancer Res. 53:16-18 (1993).
Oliner et al. Nature. 358:80-83 (1992).
Reifenberger et al. Cancer Res. 53:2736-2739 (1993).
Sheikh et al. Cancer Res. 53:3226-3228 (1993).
Bueso-Ramos et al. Blood. 82:2617-2623 (1993).
Watanabe et al. Blood. 84:3158-3165 (1994).
Xiao et al. Nature. 375:694-698 (1995).
Marechal et al. Mol. Cell. Biol. 14:7414-7419 (1994).
Kondo et al. Oncogene. 10:(10)2001-2006 (1995).
Kondo et al. Br. J. Cancer. 74:(8)1263-1268 (1996).
Mayo et al. Cancer Res. 57:5013-5016 (1997).
Shieh et al. Cell. 91:325-334 (1997).
Hollstein et al. Nucleic Acids Res. 22:3551-3555 (1994).
Kaghad et al. Cell. 90:809-819 (1997).
Moll et al. Proc. Natl. Acad. Sci. U.S.A. 92:4407-4411 (1995).
Goldman et al. Am. J. Pathol. 148:1381-1385 (1996).
Coopes et al. Cancer Invest. 12(1):57-65 (1994).
Levine. Bioessays. 12(2):60-66 (1990).
Weinberg et al. Neur. 11:191-196 (1991).
Leach et al. Cancer Res. 53:2231-2234 (1993).
Matsumaura et al. Oncology. 53:308-312 (1996).
Xiao et al. Nature. 375:695-698 (1995).
Elenbaas et al. Mol. Med. 2:(4)439-451 (1996).
Shaulian. Oncogene. 15:2717-2725 (1997).
Baker et al. Science. 249:912-915 (1990).
Zhao et al. Biochem Pharm. 51:173-182 (1996).
Agrawal et al. Antisense Research and Applications. S. Crooke, ed. Heidelberg: Spirnger-Verlag, 1997, pp. 525-543.
Zhang et al. Biochem Pharm. 50:545-556 (1995).
Zhang et al. Biochem. Pharm. 49:929-939 (1995).
Harvey et al. Genes Dev. 5:2375-2385 (1991).
Harlow et al. J. Virol. 39:861-869 (1981).
Takahashi et al. Mol. Carcinog. 8:58-66 (1993).
Zhang et al. Intl. J. Oncol. 10:1147-1156 (1997).
Cai et al. Intl. J. Oncol. 10:953-960 (1997).
Martin et al. Nature. 375:691-694 (1995).
Williams et al. Nature Genet. 7:480-484 (1994).
Agrawal Sudhir
Chen Jiandong
Zhang Ruiwen
Degen Nancy
Hybridon, Inc.
Wang Andrew
LandOfFree
MDM2-specific antisense oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MDM2-specific antisense oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MDM2-specific antisense oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1463442